NCT05610631

Brief Summary

Registry Data from PH-patients in Switzerland, who have given consent to records for research purposes.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,000

participants targeted

Target at P75+ for all trials

Timeline
16mo left

Started Jun 2017

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress88%
Jun 2017Dec 2027

Study Start

First participant enrolled

June 1, 2017

Completed
5.4 years until next milestone

First Submitted

Initial submission to the registry

November 1, 2022

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 9, 2022

Completed
5.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

November 9, 2022

Status Verified

November 1, 2022

Enrollment Period

10.5 years

First QC Date

November 1, 2022

Last Update Submit

November 8, 2022

Conditions

Pulmonary Hypertension

Outcome Measures

Primary Outcomes (1)

  • 6-minute walking distance

    6-minute walking distance

    within the study duration e.g. up to 10 years

Secondary Outcomes (4)

  • New York Heart Association functional class

    within the study duration e.g. up to 10 years

  • NTproBNP

    within the study duration e.g. up to 10 years

  • Survival

    within the study duration e.g. up to 10 years

  • Medication

    within the study duration e.g. up to 10 years

Study Arms (5)

Pulmonary arterial hypertension

Pulmonary arterial hypertension

PH due to left heart diseases

PH due to left heart diseases

PH due to lung disease and/or hypoxia

PH due to lung disease and/or hypoxia

Chronic thromboembolic PH

Chronic thromboembolic PH

Miscellaneous PH

Miscellaneous PH

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Pulmonary Hypertension (PH)

You may qualify if:

  • Patients with PH

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Respiratory Clinic, University Hospital of Zurich

Zurich, 8091, Switzerland

RECRUITING

MeSH Terms

Conditions

Hypertension, Pulmonary

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesHypertensionVascular DiseasesCardiovascular Diseases

Study Officials

  • Silvia Ulrich, Prof. Dr.

    UniversityHospital Zurich

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Silvia Ulrich, Prof. Dr.

CONTACT

+41442552220silvia.ulrich@usz.ch

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
10 Years
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 1, 2022

First Posted

November 9, 2022

Study Start

June 1, 2017

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

November 9, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations

CH(1)